
Kardigan, Inc. (NASDAQ:KARD – Free Report) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Kardigan in a research note issued on Thursday, November 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($3.70) for the year, up from their prior forecast of ($4.01). HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Kardigan’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for Kardigan’s Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.92) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.84) EPS, FY2027 earnings at ($3.47) EPS, FY2028 earnings at ($3.70) EPS, FY2029 earnings at ($3.92) EPS and FY2030 earnings at ($0.61) EPS.
Several other analysts have also recently issued reports on the company. Cantor Fitzgerald began coverage on Kardigan in a research note on Thursday, October 29th. They issued an “overweight” rating and a $50.00 target price on the stock. Weiss Ratings lowered Kardigan from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. Leerink Partners dropped their price objective on Kardigan from $37.00 to $36.00 and set an “outperform” rating for the company in a report on Friday. UBS Group initiated coverage on Kardigan in a report on Monday, October 12th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their price objective on Kardigan from $51.00 to $46.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kardigan presently has an average rating of “Moderate Buy” and a consensus target price of $41.00.
Kardigan Stock Performance
Kardigan stock opened at $13.82 on Monday. The business’s 50-day moving average price is $15.14. The stock has a market capitalization of $1.29 billion and a price-to-earnings ratio of -4.80. Kardigan has a 1-year low of $12.23 and a 1-year high of $27.00.
Kardigan (NASDAQ:KARD – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.16.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in KARD. Russell Investments Group Ltd. bought a new stake in shares of Kardigan during the third quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Kardigan in the third quarter worth $47,000. Legal & General Group Plc purchased a new stake in Kardigan in the second quarter worth $119,000. Squarepoint Ops LLC purchased a new stake in Kardigan in the second quarter worth $247,000. Finally, Jump Financial LLC bought a new position in Kardigan in the third quarter worth $304,000.
Trending Headlines about Kardigan
Here are a few of the latest headlines about KARD:
- Positive Sentiment: HC Wainwright narrowed its projected losses for FY2026, FY2028, FY2029 and FY2030. For example, its FY2026 EPS estimate improved to ($3.70) from ($4.01), and its FY2030 estimate to ($0.61) from ($0.79). The analyst also maintained a $42 target and Buy rating. Kardigan analyst estimate revisions
- Negative Sentiment: The firm lowered its estimates for each quarter of 2027 and for FY2027, now projecting a full-year loss of ($3.47) per share versus its prior estimate of ($3.29). The increased expected losses could weigh on sentiment, despite the longer-term improvements. Kardigan analyst estimate revisions
About Kardigan
Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.
Featured Stories
- Five stocks we like better than Kardigan
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Kardigan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan and related companies with MarketBeat.com's FREE daily email newsletter.
